Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH 2017 | Transferring lessons learnt from treating ALL to AML

Saar Gill • 5 Oct 2017
ESH 2017
Acute Myeloid Leukemia Leukemia CAR-T

Reflecting upon past research is key to the development of new treatments. In this interview at the International Conference of Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Hematology (ESH), Saar Gill, MD, PhD from the University of Pennsylvania, Philadelphia, PA, reflects upon the lessons learnt from treating acute lymphoblastic leukemia and how these lessons can be applied when tackling acute myeloid leukemia using CAR T-cells or bispecific antibodies.

More from Saar Gill

16:12
Exploring the potential of CAR-T therapy in CLL
John Gribben et al. • 30 Apr 2022
25:18
Addressing the major challenges to CAR-T therapy in AML
John DiPersio et al. • 30 Apr 2022
14:18
Day 2 round up: targeting AML, progress in myeloma and allogeneic CAR-Ts
David Maloney et al. • 11 Oct 2019
13:25
CLL and CAR-T
Jordan Gauthier et al. • 11 Oct 2019

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals